Regulatory T cells and HIV-1 infection

Viral Immunology

Volumn 21, Issue 3, 2008, Pages 285-291

  Terzieva, Velislava ^a  

^a NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HYDROXYUREA; INTERLEUKIN 2;

COMPARATIVE STUDY; CONFERENCE PAPER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOTHERAPY; INFECTION CONTROL; LYMPHOCYTE FUNCTION; MONOTHERAPY; NONHUMAN; PATHOGENESIS; REGULATORY T LYMPHOCYTE; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MODELS, ANIMAL; T-LYMPHOCYTES, REGULATORY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 51849126583     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2008.0006     Document Type: Conference Paper

References (90)

1. Alegre M-L, Frauwirth KA, and Thompson CB: T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001;1:220-228.
2. + T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 2003;84:1649-1661.
3. Bangs SC, McMichael AJ, and Xu X-N: Bystander T cell activation - implications for HIV infection and other diseases. Trends Immunol 2006;27:518-524.
4. Becker C, Stoll S, Bopp T, Schmitt E, and Jonuleit H: Regulatory T cells: present facts and future hopes. Med Microbiol Immunol (Berl) 2006;95:113-124.
5. Belkaid Y, and Rouse BT: Natural regulatory T cells in infectious diseases. Nat Immunol 2005;6:353-360.
6. Bensinger SJ, Walsh PT, Zhang J, et al.: Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 2004;172:5287-5296.
7. Bentwich Z, Kalinkovich A, Weisman Z, and Grossman Z: Immune activation in the context of HIV infection. Clin Exp Immunol 1998;111:1-2.
8. Bettelli E, Dastrange M, and Oukka M: Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA 2005;102:5138-5143.
9. Bluestone JA, and Tang Q: Therapeutic vaccination using CD4+CD25 + antigen-specific regulatory T cells. Proc Natl Acad Sci USA 2004;101:14622- 14626.
10. Brenchely JM, Douek DC, Ambrozak DR, et al.: Expansion of activated human naãve T-cells precedes effector function. Clin Exp Immunol 2002;130:431-440.
11. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
12. Bunting KD: STAT5 signaling in normal and pathologic hematopoiesis. Front Biosci 2007;12:2807-2820.
13. Carson BD, and Ziegler SF: Impaired T cell receptor signaling in Foxp3+ CD4 T cells. Ann NY Acad Sci 2007;1103:167-178.
14. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV infection. Nature 1997;387:183-188.
15. Clerici M, Butto S, Lukwiya M, et al.: Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. AIDS 2000;14:2083.
16. Clerici M, and Shearer GM: A TH1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
17. Clerici M, and Shearer GM: The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994;15:575-581.
18. Jevtovic D, Salemovic D, Ranin J, Pesic I, Zerjav S, and Djurkovic-Djakovic O: The dissociation between virological and immunological responses to HAART. Biomed Pharmacother 2005;59:446-451.
19. Dagarag M, Hwee NG, Lubong R, Effros RB, and Yang OO: Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocyte. J Virol 2003;77:3077-3083.
20. Dalgleish AG, Beverly PC, Claphman PR, Crawford DH, Greves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312:763-767.
21. Deng H, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
22. Derdeyn CA, and Silvestri G: Viral and host factors in the pathogenesis of HIV infection. Curr Opin Immunol 2005;17:1-8.
23. Doisne JM, Urrutia A, Lacabaratz-Porret C, et al.: CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 2004;173:2410-2418.
24. Doranz BJ, Rucker J, Yi Y, et al.: A dual-tropic primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell 1996;85:1149-1158.
25. Douek DC, Brenchley JM, Betts MR, et al.: HIV preferentially infect HIV-specific CD4+ T cells. Nature 2002;417:95-98.
26. Fauci AS: HIV and AIDS: 20 years of science. Nat Med 2003;9:839-843.
27. Finkel TH, Tudor-Williams G, Banda NK, et al.: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995;1:129-134.
28. Fontenot J, Gavin M, and Rudensky A: FoxP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
29. Fraser JH, Rincon M, McCoy KD, and Le Gros G: CTLA-4 ligation attenuates AP-1, NFAT and NF-κB activity in activated T cells. Eur J Immunol 1999;29:838-844.
30. Ganesh L, Burstein E, Guha-Niyogi A, et al.: The gene product murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 2003;426:853-857.
31. García F, Plana M, Arnedo M, et al.: A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS 2003;17:43-51.
32. Giguère JF, Diou J, Madrenas J, Tremblay M, and Michel J: Virus attachment and replication are promoted after acquisition of host CD28 and CD152 by HIV-1. J Infect Dis 2005;192:1265-1268.
33. Grant C, Oh U, Fugo K, et al.: Foxp3 represses retroviral transcription by targeting both NF-κB and CREB pathways. PLoS Pathog 2006;2(4):e33.
34. Haase AT: Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Ann Rev Immunol 1999;17:625-656.
35. Hellerstein M, Hanley MB, Cesar D, et al.: Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999;5:83-89.
36. Hellerstein MK, Hoh RA, Hanley MB, et al.: Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J Clin Invest 2003;112:956-966.
37. Hellinger JA, Iwane MK, Smith IJ, et al.: A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. J Infect Dis 2000;181:540-547.
38. Hezenberg M, Hamman D, Schuitemaker H, and Miedema F: T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000;1:285-289.
39. Hezenberg M, Otto SA, van Bentheme BHB, et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17:1881-1888.
40. Holm GH, Zhang C, Gorry PR, et al.: Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J Virology 2004;78:4541-4551.
41. Hunt PW: Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep 2007;4:42-47.
42. Hunt PW, and Deeks SG: Immune-based therapy for HIV Infection: Are acute and chronic HIV infection different diseases? J Infect Dis 2006;194:1632-1634.
43. Huse M, Lillemeir BF, Kuhns MS, Chen DS, and Davis MM: T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol 2006;7:247-255.
44. Iellem A, Mariani M, Lang R, et al.: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ T regulatory cells. J Exp Med 2001;194:847-853.
45. Iwashiro M, Messer RJ, Peterson KE, Stromnes IM, Sugie T, and Hasenkrug KJ: Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection. Proc Natl Acad Sci USA 2001;98:226-230.
46. Kinter A, McNally J, Riggin L, Jackson R, Roby G, and Fauci AS: Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci USA 2007;104:3390-3395.
47. Klatzmann D, Champagne E, Chamaret S, et al.: T-lymphocyte T4 molecule behaves as a receptor for human retrovirus LAV. Nature 1984;312:767-768.
48. Kryworuchko M, Pasquier V, Keller H, et al.: Defective IL-2-dependent JAK/STAT signalling in the CD4 and CD8 T lymphocytes from HIV+ patients: reversal by HAART [abstract]. Second IAS Conf HIV Pathog Treat 2003 Jul 13-16, Abstract No. 468. Antivir Ther 2003;8(Suppl 1):307.
49. Kryworuchko M, Pasquier V, Keller H, et al. Defective interleukin-2-dependent STAT5 signaling in CD8 T lymphocytes from HIV-positive patients: restoration by antiretroviral therapy. AIDS 2004;18:421-426.
50. Lawn SD, Buttera ST, and Folks TM: Contribution of immune activation to the pathogenesis and transmission of HIV-1 infection. Clin Microb Rev 2001;14:753-777.
51. Lederman MM, Penn-Nicholson A, Cho M, and Mosier D: Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006;296:815-826.
52. Lori, F, Malykh AG, Cara A, Sun D, Weinstein JN, Lisziewicz J, and Gallo RC: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-805.
53. Maloy KJ, and Poweri F: Fueling regulation. IL-2 keeps Tregs fit. Nat Immunol 2005;6:1071-1072.
54. Marchetti G, Meroni L, Varchetta S, et al.: Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis 2002;186:606-616.
55. Mellors JW, Kinglsey LA, Rinaldo CR, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-579.
56. Miranda L, Schaefer BC, Kupfer A, Hu Z, and Franzusoff A: Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules. Proc Natl Acad Sci USA 2001;99:8031-8036.
57. Mitsuyasu R, Gelman R, Cherng DW, et al.: The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial-AIDS Clinical Trials Group 328. Arch Intern Med 2007;167:597-605.
58. Mitsuyasu R: Immune therapy: Non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients. J Infect Dis 2002;185(Suppl 2):S115-S122.
59. Moanna A, Dunham R, Piardini M, and Silvestri G: CD4+ T cell depletion in HIV infection. Killed by friendly fire? Curr HIV/AIDS Rep 2005;2:16-23.
60. Mohri H, Perelson AS, Tung K, et al.: Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001;194:1277-1287.
61. Muro-Cacho CA, Pantaleo GP, and Fauci AS: Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with stage of activation of the lymphoid tissue and not with stage of disease of viral burden. J Immunol 1995;154:5555-5566.
62. Nilsson J, Boasso A, Velilla PA, et al.: HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006;108:3808-3817.
63. Oswald-Richter K, Grill SM, Shariat N, Leelawong M, Sundrud MS, Haas DW, and Unutmaz D: HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol 2004;2:955-966.
64. Papagno L, Spina CA, Marchant A, et al.: Activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004;2:E20.
65. Peter F: HIV Nef. The mother of all evil? Immunity 1998;9:433-437.
66. Pomerantz RJ, and Horn DL: Twenty years of therapy for HIV-1 infection. Nat Med 2003;9:867-873.
67. Revilla Calvo C, Amsan D, and Kruisbeek AM: Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. J Exp Med 1997;186:1645-1653.
68. Rizzardi GP, Harari A, Capiluppi B, et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with HAART. J Clin Invest 2002;109:681-688.
69. Rudensky AL, and Campbell D: In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J Exp Med 2006;209:489-492.
70. Sakaguchi S: Regulatory T cells. Meden Agan Immunol Rev 2006;212:5-7.
71. Sakaguchi S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455-458.
72. Sakagushi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, and Itoh M: Immunologic tolerance maintained by CD4+CD25+ T regulatory cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
73. Schindler M, Münch J, Kutsch O, et al.: Nef-mediated TCRCD3 and MHC-I down-modulation prevents CD4+ T cell depletion in natural SIV infection. Retrovirology 2006;3(Suppl 1):S95.
74. Schindler M, Münch J, Kutsch O, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2005;125:1055-1067.
75. Sell S: Basic Immunology: Immune Mechanisms in Health and Disease. Elsevier Science, New York, 1987.
76. Sereti I, Imamichi H, Natarajan V, et al.: In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005;115:1839-1847.
77. Sivestri G, Sodora DL, Koup RA, et al.: Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003;18:441-452.
78. Stassen M, Schmitt E, and Jonuleit H: Human CD4+CD25+ T regulatory cells and infectious tolerance. Transplantation 2004;77:S23-S25.
79. Sumpter B, Dunham R, Gordon S, et al.: Correlates of preserved CD4+ T cell homeostasis during natural, nonpathogenic simian immunodeficiency virus infection of sooty mangabeys. Implications for AIDS Pathogenesis. J Immunol 2007;178:1680-1691.
80. Terzieva V, Martinova F, Markova R, et al.: Influence of CD4+CD25+ regulatory T cells on HIV-1 specific CD4+ T cell responses in HIV-1 infected Bulgarian patients [Abstract]. Tenth European AIDS Conference (EACS). Dublin, 2005, Abstr. No. PE2.4/1.
81. Terzieva V, Todorova Y, Popova D, et al.: Corrélation entre la production d'IL-2 par des cellules T CD4+ et la fonction VIH-spécifique des cellules T régulatrices [Abstract]. 4e Conférence Francophone VIH/SIDA. Paris, 2007, Abstr. No. 360.
82. Thwaites GE, Bang ND, Dung NH, et al.: The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J Infect Dis 2005;192:2134.
83. Toda A, and Piccirillo C: Development and function of naturally occurring CD4+CD25+ regulatory T cells. J Leuk Biol 2006;80:458-470.
84. Von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat Immunol 2005;6:338-344.
85. Walker M, Kasprowicz DJ, Gersuk VH, et al.: Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25-T cells. J Clin Invest 2003;112:1437-1443.
86. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, and Levy Y: Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004;104:3249-3256.
87. Wolthers G, and Miedema F: Telomeres and HIV infection: in search of exhaustion. Trends Microbiol 1998;6:144-147.
88. Yagi H, Nomura T, Nakamura K, et al.: Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004;16:1643-1656.
89. Zandman-Goddard G, and Shoenfeld Y: HIV and autoimmunity. Autoimmun Rev 2002;1:329-337.
90. Zorn E, Nelson EA, Mohseni M, et al.: IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT dependent mechanism and induces the expansion of these cells in vivo. Blood 2006;108:1478-1484.